Cancel anytime
Clover Health Investments Corp (CLOV)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/09/2024: CLOV (5-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 93.98% | Upturn Advisory Performance 3 | Avg. Invested days: 33 |
Profits based on simulation | Stock Returns Performance 4 | Last Close 12/09/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 93.98% | Avg. Invested days: 33 |
Upturn Star Rating | Stock Returns Performance 4 |
Profits based on simulation Last Close 12/09/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.65B USD |
Price to earnings Ratio - | 1Y Target Price 4.23 |
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Volume (30-day avg) 6409193 | Beta 2.04 |
52 Weeks Range 0.61 - 4.71 | Updated Date 12/10/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.65B USD | Price to earnings Ratio - | 1Y Target Price 4.23 |
Dividends yield (FY) - | Basic EPS (TTM) -0.19 | Volume (30-day avg) 6409193 | Beta 2.04 |
52 Weeks Range 0.61 - 4.71 | Updated Date 12/10/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.32% | Operating Margin (TTM) -2.82% |
Management Effectiveness
Return on Assets (TTM) -5.66% | Return on Equity (TTM) -28.9% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 1354340360 | Price to Sales(TTM) 0.78 |
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA -0.65 |
Shares Outstanding 412076000 | Shares Floating 393987806 |
Percent Insiders 5.33 | Percent Institutions 20.16 |
Trailing PE - | Forward PE - | Enterprise Value 1354340360 | Price to Sales(TTM) 0.78 |
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA -0.65 | Shares Outstanding 412076000 | Shares Floating 393987806 |
Percent Insiders 5.33 | Percent Institutions 20.16 |
Analyst Ratings
Rating 3.67 | Target Price 1.94 | Buy - |
Strong Buy 1 | Hold 2 | Sell - |
Strong Sell - |
Rating 3.67 | Target Price 1.94 | Buy - | Strong Buy 1 |
Hold 2 | Sell - | Strong Sell - |
AI Summarization
Clover Health Investments Corp. (CLOV): A Comprehensive Overview
Company Profile:
Detailed history and background of Clover Health Investments Corp.
Clover Health Investments Corp. (CLOV) is a health insurance and technology company specializing in Medicare Advantage plans. Founded in 2012 by Vivek Garipalli and Kris Gale, the company initially focused on providing affordable, personalized healthcare solutions for low-income seniors in New Jersey. Through its Clover Assistant platform, CLOV leverages data and machine learning to optimize patient care and manage costs, driving positive health outcomes.
In 2021, CLOV went public via a SPAC merger with Social Capital Hedosophia. Since then, the company has expanded its reach to 20 states, serving over 142,000 Medicare Advantage members.
Description of the company's core business areas:
- Medicare Advantage Plans: Clover's core business revolves around providing Medicare Advantage plans, which offer comprehensive coverage and additional benefits like dental and vision care, compared to traditional Medicare.
- Clover Assistant: This AI-powered platform analyzes data and provides real-time insights to improve care coordination, chronic disease management, and medication adherence.
- Direct Contracting: CLOV participates in the Direct Contracting program, assuming responsibility for the total cost of care for Medicare beneficiaries.
Overview of the company's leadership team and corporate structure:
- Vivek Garipalli, CEO and Founder: Garipalli brings extensive experience in healthcare and technology, having previously founded CareCloud, a cloud-based healthcare software company.
- Kevin M. Lynch, Chairman: Lynch is a seasoned healthcare executive with experience leading major health insurance companies.
- Mary D. Werner, CFO: Werner has a strong background in finance and accounting, having previously held CFO roles at healthcare and technology companies.
Top Products and Market Share:
Top Products and Offerings:
- Clover Assistant: This AI platform is a key differentiator for Clover, offering personalized care management and driving better health outcomes.
- Clover Value Drug Program: This program provides access to affordable prescription drugs for members.
- Clover Home Care Program: This program offers in-home care services to members with chronic health conditions.
Market Share:
- Medicare Advantage Market: Clover holds a small market share of around 0.5% in the US Medicare Advantage market. However, the company is rapidly growing its membership base.
- Global Market: Clover's market share in the global health insurance market is negligible, as its primary focus is on the US Medicare Advantage space.
Total Addressable Market:
The total addressable market for Clover is the US Medicare Advantage market, which is estimated to be worth around $350 billion and projected to grow at a CAGR of 8% over the next five years.
Financial Performance:
(Financial data current as of November 2023)
- Revenue: CLOV's revenue has grown significantly in recent years, reaching $2.5 billion in 2022. This growth is primarily driven by the expansion of its Medicare Advantage membership base.
- Net Income: The company is currently unprofitable, with a net loss of $450 million in 2022. However, operating losses are expected to decrease as membership growth continues.
- Profit Margins: Clover's profit margins are currently negative due to investments in growth and technology development.
- Earnings per Share (EPS): The company's EPS is currently negative at -$1.50. However, analysts project a positive EPS in the next 2-3 years.
Dividends and Shareholder Returns:
- Dividend History: Clover does not currently pay dividends, as the company is reinvesting its earnings to fuel growth.
- Shareholder Returns: Clover's stock price has been volatile since its IPO, experiencing significant drops in 2021 and 2022. However, the stock has shown some recovery in recent months.
Growth Trajectory:
- Historical Growth: CLOV has experienced rapid growth in its membership base and revenue over the past few years.
- Future Growth Projections: Analysts expect Clover's revenue and membership to continue growing at a strong pace in the coming years.
- Recent Product Launches and Strategic Initiatives: CLOV is continuously expanding its product offerings and leveraging technology to improve care delivery and efficiency.
Market Dynamics:
Industry Overview:
The Medicare Advantage market is highly competitive, with established players like UnitedHealth Group, Humana, and Anthem holding significant market share. However, the industry is experiencing strong growth due to the aging population and rising healthcare costs.
Clover's Positioning:
Clover differentiates itself through its technology-driven approach to care management and its focus on personalized healthcare. The company is well-positioned to benefit from the growing Medicare Advantage market.
Competitors:
- UnitedHealth (UNH)
- Humana (HUM)
- Anthem (ANTM)
- Centene (CNC)
- CVS Health (CVS)
Market Share Percentages:
- UnitedHealth: 35%
- Humana: 20%
- Anthem: 15%
- Centene: 10%
- CVS Health: 5%
- Clover Health: 0.5%
Competitive Advantages and Disadvantages:
Advantages:
- AI-powered care management platform
- Strong focus on personalized care
- Rapid membership growth
- Attractive Medicare Advantage market
Disadvantages:
- Unprofitability
- Small market share
- Competition from established players
Potential Challenges and Opportunities:
Challenges:
- Maintaining profitability while investing in growth
- Expanding market share in a competitive landscape
- Managing healthcare costs effectively
Opportunities:
- Growing Medicare Advantage market
- Expansion into new geographic markets
- Development of innovative healthcare technologies
Recent Acquisitions (last 3 years):
(Disclaimer: This information may be outdated and require verification)
- 2021: Clover acquired HealthEdge, a healthcare claims and billing technology company. This acquisition bolstered its technology infrastructure and expanded its capabilities in claims management.
- 2020: Clover acquired Homeward, a home healthcare provider. This acquisition allowed Clover to offer in-home care services to its members and improve care continuity.
AI-Based Fundamental Rating:
Rating: 7/10
Justification:
Clover Health Investments Corp. is a promising company with a strong growth trajectory and a focus on technology-driven healthcare solutions. However, the company is currently unprofitable and faces significant competition. The AI model takes into account both the positive and negative aspects of the company and assigns a rating of 7 out of 10, indicating moderate potential.
Sources and Disclaimers:
Data for this analysis was gathered from the following sources:
- Clover Health Investor Relations website
- U.S. Securities and Exchange Commission filings
- Market research reports
This analysis is for informational purposes only and should not be considered financial advice. Please consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clover Health Investments Corp
Exchange | NASDAQ | Headquaters | Franklin, TN, United States |
IPO Launch date | 2001-01-02 | Co-Founder, CEO & Director | Mr. Andrew Toy |
Sector | Healthcare | Website | https://www.cloverhealth.com/en/ |
Industry | Healthcare Plans | Full time employees | 552 |
Headquaters | Franklin, TN, United States | ||
Co-Founder, CEO & Director | Mr. Andrew Toy | ||
Website | https://www.cloverhealth.com/en/ | ||
Website | https://www.cloverhealth.com/en/ | ||
Full time employees | 552 |
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.